Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy

BACKGROUND: Treatment options for many cancers include immune checkpoint inhibitor (ICI) monotherapy and combination therapy with impressive clinical benefit across cancers. We sought to define the comparative cardiac risks of ICI combination and monotherapy. METHODS: We used VigiBase, the World Hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cone, Eugene B., Haeuser, Lorine, Reese, Stephen W., Marchese, Maya, Nguyen, David-Dan, Nabi, Junaid, Chou, Wesley H., Noldus, Joachim, McKay, Rana R., Kilbridge, Kerry Laing, Trinh, Quoc-Dien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624428/
https://www.ncbi.nlm.nih.gov/pubmed/36318537
http://dx.doi.org/10.1371/journal.pone.0272022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624428/
https://www.ncbi.nlm.nih.gov/pubmed/36318537
http://dx.doi.org/10.1371/journal.pone.0272022

Ejemplares similares